Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 376 participants.

Also called NCT06735534

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 376 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06735534
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Taiwan (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06735534. Allocation not applicable; no masking; primary purpose treatment. Start 2025-06-03 (actual); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
Acronym
ReMATCH
Condition
Persistent Atrial Fibrillation
Intervention (Device)
FARAPULSE™ Pulsed Field Ablation System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct06735534
Content hash
af66369769d333d2acb575be4cfe81f16c1f1fdc45a6bb453b03fd1aef4c2a5c